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Purpose: To define importance values assigned to attributes of biological agents (BAs) by 
Spanish patients with rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, and 
psoriatic arthritis) and rheumatologists.
Patients and methods: This was an observational, cross-sectional design based upon a rank-
based full-profile conjoint analysis. A literature review and four focus groups were undertaken 
to identify attributes and levels. An orthogonal matrix, combining the selected levels of attri-
butes, was used to define scenarios. Participants ranked eight scenarios from 1 (most preferred) 
to 8 (least preferred). The relative importance (RI) of attributes was calculated. Multivariate 
regression analysis was performed to identify the characteristics that influenced the values of 
RI. A total of 488 patients (male 50.9%, mean age 50.6 [standard deviation {SD} 12.06] years, 
rheumatoid arthritis 33.8%, ankylosing spondylitis 32.4%, psoriatic arthritis 33.8%; mean time 
since diagnosis 12.6 [SD 8.2] years) and 136 rheumatologists (male 50.4%, mean age 46.4 
[SD 9.1] years, mean time of practice 16.7 [SD 8.8] years) participated.
Results: The ideal BAs for patients and physicians, respectively, should allow pain relief and 
improvement of functional capacity (RI 39% and 44.7%), with low risk of adverse events (RI 24.9% 
and 30.5%), a long time prior to perceiving the need for a new dose (RI 16.4% and 12.4%), and 
self-administration at home (RI 19.7% and 12.5%), as identified through their preferences.
Conclusion: Although efficacy and safety are paramount for patients and rheumatologists 
to make a choice regarding BAs, the need for a low frequency of administration and the 
administration method also play a role as preference attributes for BAs.
Keywords: preferences, conjoint analysis, attributes, biological agents, rheumatic diseases
Introduction
Rheumatic diseases (RDs) represent a multitude of chronic degenerative, inflamma-
tory, and autoimmune conditions affecting millions of people worldwide.1 In Spain, 
the prevalence of RD can reach 23%.2 Three of the most prevalent RDs are rheumatoid 
arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA).3–6 All three 
pathologies are characterized by their potential to cause disability,7 their negative influ-
ence on patients’ quality of life (QoL)8 and functional capacity, and by the immense 
consumption of health care resources and loss of productivity they entail.9
Traditional treatment of inflammatory RDs includes the use of symptom-modifying 
therapies (nonsteroidal anti-inflammatory drugs and corticosteroids), combined with 
nonbiologic disease-modifying antirheumatic drugs (DMARDs).10,11 The develop-
ment of new biological therapies, particularly TNF inhibitors, has led to significant 
improvement in clinical outcomes, including symptoms, health-related QoL (HRQoL), 
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and functioning.12 However, this scenario is associated with 
a more complex decision-making process. These newer 
therapies present different routes of administration, increased 
or different toxicities, and higher financial costs, all of 
which may influence patient preferences and adherence to 
medications.13
Assessing and including patient preferences within 
routine clinical practice has been related to an increment in 
medication adherence, improvements in treatment outcomes, 
and reduced health care costs.13–19 Since the first studies that 
examined patient preferences for biological agents (BAs) 
in RA were published,20,21 rheumatologists have started to 
use patient-focused outcomes to improve RA treatment.22 
Nevertheless, it is possible that RD outcomes could be 
improved further if rheumatologists were aware of how 
patients used and perceived newer medications,23 thereby 
reinforcing the importance of understanding patients’ 
attitudes toward treatment and involving them in shared 
decision making.13 The aim of this study was to define the 
importance values (preferences) assigned to the attributes of 
BAs by Spanish patients with the main RDs – RA, AS, and 
PsA – and by their rheumatologists.
Materials and methods
Design
An observational cross-sectional study was conducted 
in 41 Spanish hospitals, based on a conjoint analysis 
methodology. The conjoint analysis method is particularly 
useful for quantifying preferences for a diverse range of 
health applications. It consists of a composition method, in 
which the implicit values for an attribute of an intervention 
are derived from the overall score for a profile consisting 
conjointly of two or more attributes.24 It is also used to 
understand patient preferences for health states, to value 
the various health states described by patient-reported 
outcomes and HRQoL scales,25 and to assess patients’ 
willingness to accept the therapeutic risks associated with 
more effective treatments.24 Conjoint analysis also offers 
a mechanism for patients to participate in the decision-
making process.26,27
The conjoint analysis technique uses questionnaire data. 
In the present study, a rank-based full-profile conjoint was 
applied. In this method, individuals are first presented with, 
and then asked to give an ordinal ranking to the options of 
hypothetical scenarios involving different levels of character-
istics, which have been identified as important to the question 
of interest.28 Those options that achieve the highest ranking 
are viewed as the most important. Since it is considered easy 
to answer and to analyze, this method has become popular 
for eliciting preferences for health care interventions.29
Following the International Society For Pharmacoeco-
nomics and Outcomes Research good research practices 
for conjoint analysis,24 a literature review was performed to 
identify the preliminary set of attributes and levels of BAs 
most frequently described in publications. Subsequently, 
a focus group with rheumatologists (n=5) and three focus 
groups with patients (n=5) – one for each pathology (RA, 
AS, and PsA) – were formed. Focus groups helped define, 
from the identified attributes, the final set of attributes and 
levels included in the study, reflecting both patients’ and 
professionals’ perspectives regarding BAs.
Table 1 shows the four attributes of BAs included in the 
study, with their respective levels: administration method 
(subcutaneous self-administration at home, intravenous 
administration by a health care professional at hospital), risk of 
adverse events (AEs; high risk of AEs, low risk of AEs), pain 
relief (pain relief and improvement in functional capacity, no 
pain relief and no improvement in functional capacity), and 
duration of effect (1 week, 2 weeks, 4 weeks, 8 weeks).
For definition of the scenarios, an orthogonal design was 
used. A full-choice fractional factorial design was imple-
mented using SPSS version 19.0. This orthogonal design, 
combining the levels of the attributes, resulted in eight sce-
narios, which described different alternatives of treatment 
with BAs for RA, AS, or PsA.30
A self-completion hard-copy case-report form (CRF) 
was specifically designed to collect data from participants.31 
Patient CRFs included sociodemographic (age, sex, marital 
status, place of residence, level of studies, employment status, 
and other variables) and clinical variables (height, weight, date 
of onset of first symptoms, diagnosed rheumatic illness, date 
Table 1 Attributes and levels included in the scenarios
Attribute Level
Administration method •	 subcutaneous self-administration at 
home
•	 intravenous administration by a health 
care professional at hospital
risk of adverse events •	 high risk of adverse events
•	 low risk of adverse events
Pain relief and improvement 
in functional capacity
•	 Pain relief and improvement in 
functional capacity
•	 no pain relief and no improvement in 
functional capacity
Duration of effect (time  
until perceiving the need  
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Preferences for biologic rD treatments in spain
of diagnosis, disabling symptoms and complications associ-
ated with RD, comorbidities, current treatment, and previous 
treatment), as well as participants’ preferences. In patient 
CRFs, clinical and sociodemographic data were collected 
by rheumatologists taking part in the study during routine 
practice, while patients ranked the scenarios from 1 (most 
preferred) to 8 (least preferred). In addition, professionals 
self-completed another CRF based on their sociodemographic 
data (age, sex, work center, time of professional experience) 
and preferences. Professionals ranked the scenarios from 1 
(most preferred to prescribe) to 8 (least preferred to prescribe). 
Missing data for variables are presented in Table 2.
Participants
The study protocol was approved by the ethics Committee 
of the Bellvitge Hospital Universitari (Acta 01/13, reference 
EPA047/12). All participants in the study provided written 
consent. A total of 41 hospitals in the public health sector 
where BAs for RDs were prescribed were purposefully 
identified around the country, covering the whole Spanish 
territory. A rheumatologist at each selected hospital was 
required to recruit a minimum of four to five ambulatory 
patients for each condition under study (n=12–15), as well 
as a minimum number of rheumatologists (three to four) 
working in the same or a similar health care centre.
Table 2 Patient sociodemographic and clinical variables
Patient variables Total (488) RA (165) AS (158) PsA (165) P-value
Age (years), mean (sD) 50.61 (12.06) 55.9 (11.5) 46.3 (11.4) 49.5 (11.4) ,0.001
sex ,0.001
Male (%) 50.9 26.2 71.8 55.8
Female (%) 49.1 73.8 28.2 44.2
MD 0.6% MD 0.6% MD 1.3% MD 0
Marital status 0.016
Married (%) 70.1 72.1 63.3 74.5
single (%) 14.8 10.3 22.8 11.5
cohabiting (%) 6.4 5.4 7.6 6.1
separated/divorced (%) 4.9 5.4 5.1 4.3
Widowed (%) 3.9 6.7 1.2 3.6
Place of residence 0.136
living at own home (%) 92.2 95.7 87.9 92.7
living at parents’ home (%) 5.8 2.4 9.6 5.5
living at home of others (%) 1.9 1.8 1.9 1.8
MD 0.4% MD 0.6% MD 0.6% MD 0
level of studies 0.413
Primary (%) 35.2 39.4 29.1 36.9
secondary (%) 24.8 18.8 20.2 15.2
Other (%) 40 42.2 50.7 47.9
employment status ,0.001
employed (%) 38.6 25.9 45.8 44.2
sick leave due to rD (%) 13 16.6 11.6 10.9
retired (%) 16.4 25.9 6.5 16.4
Other (%) 32 32.7 36.6 28.5
Other variables
regular alcohol consumption (%) 16 11.7 22.1 14.6 0.034
MD 1.4% MD 1.2% MD 2.5% MD 0.6%
nonsmokers (%) 49.1 53.0 47.5 46.7 0.098
Weight (kg), mean (sD) 75.8 (15.4) 71.1 (14.9) 77.6 (15.3) 78.6 (15) ,0.001
MD 0.8% MD 1.2% MD 0 MD 1.2%
height (cm), mean (sD) 166.5 (9.3) 162.7 (8.7) 169.3 (8.9) 167.4 (9) ,0.001
MD 0.8% MD 1.2% MD 0 MD 1.2%
BMi (kg/m2), mean (sD) 27.3 (4.8) 26.8 (5) 27 (4.6) 28 (4.9) 0.058
MD 0.8% MD 1.2% MD 0 MD 1.2%
charlson index, median (sD) 0.4 (0.7) 0.5 (0.8) 0.2 (0.6) 0.3 (0.7) ,0.001
MD 0.4% MD 0.6% MD 0 MD 0.6%
Time since first symptoms,  
mean (sD)
15 (9.6) 14.1 (8.5) 17.4 (11.2) 13.6 (8.5) 0.005
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Patient variables Total (488) RA (165) AS (158) PsA (165) P-value
Disabling symptoms
none 29.1% 25.5% 30.4% 31.5% 0.437
Joint rigidity 30.9% 25.5% 8.2% 18.2% 0.759
Joint swelling 17.4% 30.9% 32.9% 29.1% ,0.001
Joint pain 51.8%
MD 0.2%
58.8% 43.7% 52.7% 0.055
limitation of functional capacity 34% 37.6% 39.2% 25.5% 0.016
Others 4.3% 3.6% 7.6% 1.8% 0.033
complications associated with rD
Without complications 68.9% 22.7% 20.9% 25.2% 0.132
Amyloidosis 0.4% 0 0.2% 0.2% 0.598
Anemia 2.7%
MD 0.2%
1.8% 0.4% 0.4% 0.05
cardiac complications 1.4% 1% 0 0.4% 0.07
intestinal complications 3.5% 0.6% 2.3% 0.6% 0.015
Ocular complications 10% 2.9% 5.9% 1.2% ,0.001
renal complications 1.2% 0.4% 0.4% 0.4% 0.999
Pulmonary complications 2.7% 2.3% 0.2% 0.2% 0.001
neurological complications 0.8% 0.2% 0.4% 0.2% 0.751




12.7% 16.2% 15% 0.078
infectious and parasitic 2%
MD 0.2%
1% 0.4% 0.6% 0.519
neoplasia 0.8%
MD 0.4%
0.8% 0 0 0.043
endocrine, nutritional and metabolic 22.7%
MD 0.2%
10.5% 4.7% 7.6% 0.002
Blood and hematopoietic organs 1.6%
MD 0.2%
0.2% 0.6% 0.8% 0.406
Mental disorders 1.6%
MD 0.2%
0.2% 0.8% 0.6% 0.386
nervous system and sense organs 1.8%
MD 0.4%
1% 0.6% 0.2% 0.33
circulatory system 12.7%
MD 0.2%
5.9% 2.9% 3.9% 0.055
respiratory system 4.1%
MD 0.2%
1.4% 1.4% 1.2% 0.935
Digestive system 7%
MD 0.2%
1.6% 3.3% 2% 0.153
genitourinary system 4.1%
MD 0.2%
1.2% 1% 1.8% 0.537
skin and subcutaneous tissue 3.5%
MD 0.2%
0.4% 1.2% 1.8% 0.104




3.1% 1.2% 2% 0.148
congenital anomalies 0.2%
MD 0.2%
0.2% 0 0 0.376
Others 8.8%
MD 0.4%
2.3% 2.3% 4.3% 0.09
Note: Percentages calculated on data available.
Abbreviations: MD, missing data; BMi, body mass index; rA, rheumatoid arthritis; As, ankylosing spondylitis; PsA, psoriatic arthritis; sD, standard deviation; rD, rheumatic 
disease.
Patients’ inclusion criteria included having been diag-
nosed with RA, AS, or PsA at least 2 years prior to their inclu-
sion and currently or previously (#1 year ago) receiving BAs 
for a minimum of 1 year. Exclusion criteria included a need 
to translate questionnaire, coexistence of the studied RDs, 
incapacity to participate due to clinical, physical, or intel-
lectual factors according to clinician judgment, and currently 
taking part in a clinical trial. Rheumatologists were required 
to have at least 3 years’ experience in the use of BAs, and 
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Preferences for biologic rD treatments in spain
statistical analysis
A descriptive statistical analysis was performed for sociode-
mographic, clinical, and treatment variables. A rank-ordered 
logit model was applied to estimate the preferences or partial 
utilities of each attribute, which indicated the perceived value 
of the feature. The relative importance (RI) of attributes 
was calculated from these partial utilities (the utility ranges 
of an attribute divided by the sum of the ranks of the four 
attributes of each individual), allowing the comparison of 
values between the two groups. To identify the clinical and 
sociodemographic characteristics that influenced the value of 
RI given to each attribute by both patients and rheumatolo-
gists, a multiple-regression analysis was performed where 
the values of importance were considered dependent and 
the clinical and sociodemographic variables independent 
variables. All variables were included in the analysis, 
but to reduce the number of independent variables and to 
avoid problems of collinearity, a stepwise algorithm was 
implemented. The software SPSS version 19.0 was used for 
all statistical tests, and a significance level of P,0.05 was 
assumed. To compare the values obtained in the different 
groups, the χ2 test was performed for qualitative variables. 
Parametric distributions were analyzed with analysis of 
variance, while nonparametric distributions were examined 
with the Kruskal–Wallis test.
Results
Descriptive analysis
A total of 488 patients were included, distributed equally 
among diseases (RA 33.8%, AS 32.4%, and PsA 33.8%). 
The sample mean age was 50.61 (standard deviation [SD] 
12.06) years. In the RA sample, 73.8% were females, while 
in the AS and PsA groups, males accounted for 71.8% and 
55.8%, respectively (Table 2).
Average sample weight and height were 75.8 kg and 
166.5 cm, respectively, with significant differences between 
diseases. The mean Charlson index score was 0.4 (SD 0.7), 
with significant differences (P=0.001) among pathologies 
(RA 0.5 [SD 0.8], AS 0.2 [SD 0.6], and PsA 0.3 [SD 0.7]). At 
inclusion in the study, the mean time since the diagnosis of the 
RDs was 12.6 (SD 8.2) years, while the mean time since the 
onset of symptoms was 15 (SD 9.6) years. The most common 
disabling symptoms reported were joint pain (SD 51.8%) and 
limitation of functional capacity (34%) (Table 2). The sample 
mean body mass index was 27.3 kg/m2 (SD 4.8), and 43.9% 
of the population studied did not present comorbidities (sec-
ondary diagnoses). According to physician judgment, most 
of the patients did not have complications associated with 
their RD (68.9%), considered as an unfavorable evolution 
of the disease. The complications taken into account were 
amyloidosis, anemia, cardiac, intestinal, ocular, renal, lung, 
and neurological complications, and others, but only ocular 
(10%), intestinal (3.5%), and pulmonary (2.7%) complica-
tions showed significant differences between pathologies 
(Table 2). Of comorbidities reported, the most common were 
endocrine, nutritional, and metabolic conditions (22.7%), and 
these, together with neoplasia, were the comorbid conditions 
with marked differences between pathologies.
Table 3 shows the BAs most frequently received by 
patients – mainly etanercept (27.3%), adalimumab (26.2%), 
Table 3 number and percentage of patients receiving treatment with BAs at the time of study inclusion, and previous treatment
Actual treatment with BAs Previous treatment with BAs
Total, % RA AS PsA Total, % RA AS PsA
etanercept 133
27.3%
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Figure 1 Patients’ (A) and rheumatologists’ (B) utility values.
Note: estimated utility values for each attribute in the sample of patients and rheumatologists.
Abbreviation: Aes, adverse events.
and infliximab (23.2%) – with the mean duration of treatment 
being 49.7 (SD 36.7) months, as well as those BAs previ-
ously received – mainly adalimumab (10.7%), infliximab 
(9.4%), and etanercept (9%) – with an average duration of 
43.8 (SD 37.5) months. With regard to rheumatologists, the 
sample consisted of 136 participants: 50.4% males with a 
mean age of 46.4 (SD 9.1) years. The mean time of profes-
sional experience was 16.7 (SD 8.8) years.
Preferences for BA attributes
The conjoint analysis models proved to fit: Pearson’s R=0.991 
(P,0.001) and Kendall’s τ=0.929 (P,0.001) for patients, 
and Pearson’s R=0.996 (P,0.001) and Kendall’s τ=1 
(P,0.001) for rheumatologists. Figure 1 demonstrates that 
each attributes’ preferred levels for both patients and rheu-
matologists were similar: subcutaneous self-administration at 
home (utility values 0.26 and 0.37), low risk of AEs (utility 
values 0.81 and 1.03), pain relief and improvement of func-
tional capacity (utility values 1.26 and 1.59), and duration 
of effect (time until perceiving the need for a new dose) of 
8 weeks (utility values 0.53 and 0.61), respectively.
Figure 2 shows the RI given by both patients and rheuma-
tologists to the attributes of BAs and for specific rheumatic 
conditions. Based on the utility values calculated by the 
model, both patients, with independence of the diagnosis, 
and physicians placed more importance on the pain relief and 
improvement in functional capacity attribute (RI 39% and 
44.7%), followed by the risk of AEs (RI 24.9% and 30.5%), 
administration method (RI 19.7% and 12.5%), and duration 
of effect (time until perceiving the need for a new dose) 
(RI 16.4% and 12.4%), respectively. However, significant 
differences (P,0.002) were found on the RI given to the 
four attribute values by both groups of participants. Patients 
placed higher importance on the administration method and 
duration of effect (time until perceiving the need for a new 
dose) attributes, compared to rheumatologists, while the 
latter gave more importance to pain relief, improvement in 
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Preferences for biologic rD treatments in spain
With regard to the time until perceiving the need for a new 
dose, both patients and professionals preferred 2–4 weeks 
over 1–2 weeks. Assuming that pain relief and risk of AEs 
were equal, patients’ and professionals’ utility values for 
BAs administered subcutaneously increased by 10% and 
9% when the time until perceiving the need for a new dose 
was incremented from 4 to 8 weeks and by 20% and 17% 
when it was incremented from 1 to 8 weeks, respectively 
(Figure 3A and C). For BAs administered intravenously, 
the upturns for patients and professionals were 13% and 
12%, and 25% and 23%, respectively (Figure 3B and D). 
These results demonstrate that both patients and rheuma-
tologists gave higher importance to lower frequencies of 
administration or longer time until perceiving the need for 
a new dose.
The ideal BA for both patients and professionals would be 
a drug that relieved pain and improved ability to perform daily 
activities, with a low risk of side effects, self-administered at 
home subcutaneously, and with longer time until perceiving 
the need for a new dose (8 weeks).
Multivariate-regression analysis
Table 4 presents the results of the multivariate analysis, 
identifying the sociodemographic and clinical variables that 
affected the RI of each attribute. For patients, sex, pathology, 
symptoms, complications associated with the RD, and geni-
tourinary comorbidities influenced the importance given to 
the risk of AEs. In general, females, patients diagnosed with 
AS, patients with articular rigidity, subjects without limita-
tions to their functional capacity, and those with intestinal 
complications or genitourinary comorbidities gave greater 
importance to the risk of AEs. The variable that influenced 
the importance given to the relief of pain and improvement 
in functional capacity was disease symptoms. Patients 
presenting articular swelling and those without limitations 
in functional capacity gave less importance to the relief of 
pain. Mode of administration, age, sex, and the presence of 
intestinal complications influenced their preferences. Older 
patients, females, and those who presented an intestinal 
complication granted less importance to the mode of admin-
istration of BAs.
Figure 2 Relative importance values given by both patients and rheumatologists to the attributes of biological agents and for specific rheumatic conditions.
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For rheumatologists, age and length of their professional 
experience influenced the importance given to the risk of 
AEs. Older professionals and rheumatologists with less time 
practicing the specialty granted less importance to the risk 
of AEs. Sex influenced the importance given to the relief 
of pain and improvement in functional capacity. Females 
gave less importance to the relief of pain and improvement 
in functional capacity.
Discussion
In recent years, BA options for patients with RDs have 
continued to expand, creating opportunities for improved 
outcomes, such as decreased pain, disability, and mortal-
ity. However, patients as well as physicians are faced with 
increasingly complex decisions about how and when a 
medication should be prescribed.32 It has been reported 
that health care professionals more often rely on personal 
Figure 3 Pareto diagrams representing patients’ and professionals’ utility values for subcutaneous and intravenous treatment alternatives.
Notes: (A) Utility values for patients regarding subcutaneous treatment. (B) Utility values for patients regarding intravenous treatment. (C) Utility values for professionals regarding 
subcutaneous treatment. (D) Utility values for professionals regarding intravenous treatment. Duration of effect indicates the time until perceiving the need for a new dose (1 
week, 4 weeks, and 8 weeks).
Abbreviations: Aes, adverse events; BA, biological agent.
beliefs and experiences to make clinical decisions than on 
scientific evidence,33–35 and that those can differ from the 
views of their patients.36 There is a need to provide patients 
with individualized treatment strategies and to enable their 
participation in medical decision making.37 One essential 
factor that professionals must consider for reaching this goal 
is inquiring about patients’ preferences.38
Results demonstrated that patients’ and professionals’ 
preferences were similar, the most to least preferred attributes 
being pain relief and improvement of functional capacity, risk 
of AEs, administration mode, and frequency of administra-
tion (time until perceiving the need for a new dose). The ideal 
treatment for both patients and professionals would be a BA 
that relieved pain and improved the ability to perform daily 
activities, with a low risk of AEs, self-administered at home 
subcutaneously, and with a greater time before perceiving 
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Table 4 Factors influencing patients’ and rheumatologists’ preferencesa




sex (female vs male) -10.45 0.0142
intestinal complications (yes vs no)b -11.05 0.024
smoking habits: nonsmoker ,1 year (vs smoker) -0.61 0.8162
smoking habits: nonsmoker 1 year (vs smoker) 1.12 0.6246
smoking habits: never-smoker (vs smoker) 0.16 0.1019
Joint swelling (yes vs no) 4.27 0.0939
Joint rigidity (yes vs no) -3.21 0.1185
complications associated with rD (yes vs no)b 2.01 0.1111
cardiac complications (yes vs no)b -3.65 0.0619
renal complications (yes vs no)b -18.66 0.0227
Pulmonary complications (yes vs no)b -11.21 0.0064
neurological complications (yes vs no)b 9.4 0.0443
genitourinary comorbidities not associated with rD (yes vs no)b 0.12 0.1221
skin comorbidities not associated with rD (yes vs no)b -2.86 0.1418
risk of side effects
sex (female vs male) 5.08 0.0013
Pathology (As vs rA) 4.12 0.0367
Joint rigidity (yes vs no) 4.48 0.0057
limitation of functional capacity (yes vs no) -5.42 0.0008
intestinal complications (yes vs no)b 10.45 0.0083
Ocular complications (yes vs no)b -5.55 0.0255
genitourinary comorbidities (yes vs no)b 7.74 0.0237
BMi -0.28 0.0666
Pathology (PsA vs rA) 1.58 0.3854
Pulmonary complications (yes vs no)b 8.42 0.0738
Osteomyoarticular comorbidities (yes vs no)b -4.38 0.1352
relief of pain
Joint swelling (yes vs no) -2.96 0.0283
limitation of functional capacity (yes vs no) 6.76 0.0011
Age -1.49 0.5293
Pathology (As vs no As) 4.28 0.0616
Pathology (PsA vs no PsA) -6.72 0.0134
renal complications (yes vs no)b 12.33 0.1574
Blood complications (yes vs no)b 10.15 0.1423
skin complications (yes vs no)b 11.94 0.0852
Duration of effect
sex (female) 2.37 0.0836
BMi 0.22 0.1273
regular alcohol consumption (no vs yes) -3.17 0.084
symptom duration -0.13 0.0581
endocrine comorbidities (yes vs no)b -2.3 0.1521
circulatory comorbidities (yes vs no)b 3.63 0.0828
congenital anomalies/comorbidities (yes vs no)b -22.11 0.1096
Rheumatologists
Administration method nA nA
risk of side effects
Age -1.31 0.0007
Duration of professional exercise 1.03 0.0099
relief of pain
sex (female vs male) -6.39 0.0329
Age 0.3 0.0662
Time until perceiving the need for a new dose
Age 0.59 0.0396
sex (female vs male) 3.88 0.0256
Duration of professional practice -0.61 0.04
Notes: aresults from multivariate regression analysis; baccording to physician’s judgment. The coefficients of the quantitative variables indicate the magnitude of change in 
the independent variable for each unit of increase in the dependent variable. In the qualitative variables, coefficients indicate the change in the variable response with respect 
to the reference category (positive values indicate increase; negative values indicate decrease).
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key aspects for participants, both the frequency and method 
of administration play an important role as attributes of 
BAs in Spain. In this study, both patients and professionals 
preferred a low frequency of administration. Huynh et al32 
recently presented similar results. In an observational study 
performed in Denmark including RA patients naïve to and 
treated with BAs, as well as physicians and nurses, low 
treatment frequency was the preferred attribute for patients, 
followed by a more conservative route of administration. The 
authors concluded that the route and frequency of adminis-
tration could influence patients’ adherence to and satisfac-
tion with the treatment. Parallel outcomes were reported 
by Augustovski et al,39 who performed a discrete-choice 
experiment on patients with RA naïve to BAs. These authors 
showed that avoidance of systemic AEs was the preferred 
attribute of BAs, followed by frequency of administration, 
efficacy, and route of administration.
In the present work, the RI given to the mode of adminis-
tration and to the time until the perception of the need for a new 
dose was significantly greater in patients, while professionals 
placed more importance on the relief of pain, improvement in 
functional capacity, and risk of AEs. These differences could 
be due to patients granting more value to the characteristics 
regarding treatment comfort or convenience, while these 
aspects are not so valued by rheumatologists. These results are 
also in line with the previous findings of Huynh et al,32 where 
RA patients and health professionals showed similar prefer-
ences regarding the route and frequency of administration of 
BAs, especially with those patients receiving subcutaneous 
treatment, but with differences in magnitude.
The importance of the administration route was also 
demonstrated in a study performed in Italy,40 in which 
patients with RA addressed their perceptions of their current 
treatment and preferences for anti-TNF agents. The findings 
showed that 50.2% of patients preferred intravenous admin-
istration, mainly due to the reassuring effect of the presence 
of health care personnel, while 49.8% chose subcutaneous 
administration for its convenience. Moreover, in a study con-
ducted in the UK41 to assess the preferences of patients with 
RA receiving anti-TNF therapy or conventional DMARDs, 
the route of administration was the single feature of anti-
TNF therapy that concerned patients the most. Subcutaneous 
injection was the first choice for those on anti-TNF therapy 
(41%) and those not yet receiving BAs (52.5%).
This analysis has some limitations, due to its design. The 
number and definition of attributes and factor levels is the 
critical step in any conjoint analysis, and although it followed 
the available guidelines, as it was based on a literature 
review and the opinion of patients and professionals, it may 
be subject to biases, due to participants’ cultural context 
or experience. Further research is needed to determine the 
relative effect of other potentially important attributes not 
included in this study, and to evaluate the stability of results 
across different populations. Moreover, patient preferences 
need to be explored in more depth in populations at a higher 
risk of poor communication with their physicians (those with 
low literacy, lower levels of education, and immigrants) and 
at risk of incomplete understanding or misunderstanding of 
the risks and benefits of these medications. Considering that 
this study was restricted to patients and rheumatologists 
from the Spanish public health system, its results must be 
extrapolated carefully to subjects from different backgrounds 
and cultures, patients with more severe diseases or institu-
tionalized, or rheumatologists with less clinical experience 
than the included population, and must be interpreted within 
the context they were performed. Furthermore, a period of 
at least 1 year in biological DMARD (bDMARD) experi-
ence was chosen to select patients for this study, so it has 
to be considered that patients with early discontinuation of 
bDMARDs could have expressed different preferences.
For missing data, there are no objective criteria to 
clarify the maximum percentage of omissions that can be 
accepted, so each researcher must be responsible for their 
own decisions.42 In the case of this study, given that all data 
were available for main variables (conjoint analysis), and 
that the maximum percentage of missing data for secondary 
variables was just 2.5%, missing values were not imputed, 
and results were calculated from available data. Nonetheless, 
this study provides very interesting results.
To the authors’ knowledge, it is the first time the prefer-
ences of treatment-experienced Spanish patients with differ-
ent RDs, and rheumatologists, have been examined and their 
needs and perceptions regarding BAs identified and compared 
by means of a ranking-based conjoint analysis. Understand-
ing patient needs provides the physician with the basis for 
the right therapeutic choice.43,44 At the same time, physician 
preference has been shown to be an important determinant of 
patient acceptance of biological therapy,45 so the physician 
perspectives were also assessed in this study and compared 
to those of patients. This approach allowed us to detect dif-
ferences between these two perspectives.
The knowledge produced in this analysis could contribute 
to a more informed decision-making process and a better choice 
of treatments.46 Professionals should thus explore the prefer-
ences of patients by involving them in treatment decisions,28 in 
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Preferences for biologic rD treatments in spain
Conclusion
The assessment of patients’ and professionals’ preferences 
for the different attributes of BAs in the treatment of RDs is 
a necessary step toward improving results, by ensuring satis-
faction and adherence findings that could contribute to better 
outcomes. Spanish patients with RDs’ and rheumatologists’ 
preferences for BAs were similar, preferring medication that 
relieves pain and improves ability to perform daily activities, 
with a low risk of AEs, self-administered at home subcutane-
ously, and with a greater time before perceiving the need for 
a new dose. Although efficacy and safety are key aspects for 
participants, both the frequency and method of administration 
play an important role as attributes of BAs.
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